Acadia taps 25-year HR veteran for chief people officer role
Acadia Pharmaceuticals Inc. has appointed Carl Segerstrom as its new Chief People Officer, effective July 6. Segerstrom, who brings over 25 years of global human resources experience from the biopharmaceutical industry, will lead the company's people and culture strategy to support its growth as a neurological and rare disease company. He previously held several senior HR leadership roles at Merck, including Chief Talent Officer.
Price to book forward of ACADIA Pharmaceuticals Inc. – LSX:603035
The article discusses the "Price to book forward" metric for ACADIA Pharmaceuticals Inc. (LSX:603035). It appears to be a financial data snippet from TradingView, indicating that the market for this stock was closed with no trades recorded. The content does not provide specific financial values but rather sets the context for where such data would typically be displayed.
ACAD - Acadia Pharmaceuticals Inc Forecast, Target Price
This article provides comprehensive financial data for Acadia Pharmaceuticals Inc. (ACAD), including key metrics like market capitalization, P/E ratio, EPS forecasts, and sales performance. It also details insider and institutional ownership, profitability ratios, and various stock performance indicators, alongside an analyst consensus target price of $32.30.
Price to sales forward of ACADIA Pharmaceuticals Inc. – NASDAQ:ACAD
This article provides access to the "Price to sales forward" financial metric for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on TradingView. It indicates that the market was closed at the time of publication and offers no trades. The content primarily focuses on navigation to financial data and various features available on the TradingView platform.
ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now
Hagens Berman, a national trial law firm, is alerting investors of Acadia Pharmaceuticals (NASDAQ: ACAD) to a securities class action lawsuit. The lawsuit alleges that Acadia misrepresented facts concerning its supplemental new drug application ("sNDA") for NUPLAZID® (pimavanserin) for dementia-related psychosis, which was ultimately rejected by the FDA. Investors who suffered significant losses during the Class Period of June 15, 2020, to April 4, 2021, are encouraged to contact Hagens Berman for legal advice.
ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds
ACADIA Pharmaceuticals (ACAD) shares are in focus after European regulators issued a positive opinion on Daybue for Rett syndrome, causing a recent rally. Despite a 16.34% one-month return, the stock is still down 4.15% year-to-date and is considered 12.3% undervalued with a fair value of $28.75. The company's concentrated portfolio means execution is critical, and while success can have an outsized impact, it also carries concentration risk.
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress
H.C. Wainwright reaffirmed its Buy rating and $37 price target for Acadia Pharmaceuticals (NASDAQ:ACAD) after the CHMP issued a positive opinion for DAYBU (trofinetide) in Europe. This decision reverses a previous refusal and recommends marketing authorization for neurobehavioral symptoms of Rett syndrome in patients aged five and older. Other analysts like Canaccord, Mizuho, and Baird also maintained positive ratings, while Oppenheimer kept a Perform rating.
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com
This article announces the filing of Form 4 for ACADIA Pharmaceuticals Inc. on June 29. It includes basic information about the company and its stock performance, along with a statement from Reuters. The primary content is a headline and brief stock data.
ACADIA PHARMACEUTICALS (ACAD) officer sells 11,421 shares under 10b5-1 plan
ACADIA PHARMACEUTICALS' Principal Accounting Officer, James Kihara, sold 11,421 shares of common stock at a weighted average price of $26.0846 per share. This open-market transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. Following the sale, Kihara directly holds 13,088 shares of ACADIA PHARMACEUTICALS.
ACADIA Pharmaceuticals Price Target Raised to $35.00/Share From $32.00 by Citigroup
Citigroup has increased its price target for ACADIA Pharmaceuticals from $32.00 to $35.00 per share. This adjustment indicates a more optimistic outlook by the firm on the company's future stock performance.
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher after the European Medicines Agency (CHMP) recommended granting marketing authorization for its drug DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in the EU. This follows an earlier negative vote and is based on positive Phase 3 study results. The stock shows strong short-term momentum but is in overbought territory, with a mixed profile regarding value and momentum indicators.
Why ACADIA Pharmaceuticals (ACAD) Is Up 17.1% After EMA Backs DAYBU For Rett Syndrome
ACADIA Pharmaceuticals saw its stock rise by 17.1% after the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for DAYBUE (trofinetide) to treat Rett syndrome in the EU. This potential approval would make DAYBUE the first approved therapy for Rett syndrome in 30 European countries, significantly impacting ACADIA's future growth. The company's investment narrative focuses on leveraging revenue from NUPLAZID while DAYBUE becomes a key second pillar, with reaffirmed 2026 revenue guidance of US$1.22 billion to US$1.28 billion.
ACADIA Pharmaceuticals Up Nearly 11%, On Track for Largest Percent Increase Since May 2025 -- Data Talk
ACADIA Pharmaceuticals (ACAD) shares increased by nearly 11% today, putting the company on track for its largest single-day percentage gain since May 2025. This significant rise highlights strong investor interest, potentially driven by recent developments or market optimism surrounding the company's prospects.
[144] ACADIA PHARMACEUTICALS INC SEC Filing
This article details an SEC Form 144 filing by ACADIA PHARMACEUTICALS INC (ACAD) regarding a proposed sale of 11,421 shares of common stock with an aggregate market value of $297,000.00. The shares were acquired on February 23, 2024, as compensation from the issuer. The filing was accepted by the SEC EDGAR system on June 26, 2026, at 03:09 PM.
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
Acadia Pharmaceuticals (ACAD) stock jumped following a positive recommendation from the European Medicines Agency's CHMP for its drug DAYBU (trofinetide) for treating Rett syndrome. This follows an earlier negative vote, and the recommendation is based on strong Phase 3 LAVENDER study results. Despite the positive news, technical analysis shows the stock is in overbought territory with a recent "death cross" indicating caution for long-term investors.
Acadia wins EU backing for Rett syndrome drug (ACAD:NASDAQ)
Acadia Pharmaceuticals (ACAD) saw its stock rise by approximately 13% after an expert panel of the European Medicines Agency (EMA) recommended marketing authorization for Daybu. Daybu is Acadia's treatment for Rett syndrome, a rare genetic neurodevelopmental disorder. This endorsement marks significant progress for the drug in the European Union.
Biotech Blows Into Breakout Territory On A Surprising Reversal
Acadia Pharmaceuticals (ACAD) saw its stock jump after European regulators surprisingly reversed an earlier decision and recommended approval for its Rett syndrome drug, Daybue. This reversal propelled Acadia's stock closer to a breakout, providing a significant boost for the company. Rett syndrome is a rare neurological condition primarily affecting females, causing severe developmental regression.
Acadia Pharmaceuticals Receives Chmp Positive Opinion for Daybu Trofinetide for Treatment of Neurobehavioral Symptoms of Rett Syndrome
Acadia Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for DAYBU (trofinetide). This recommendation is for the marketing authorization of DAYBU to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved by the European Commission, DAYBU would be the first therapy for this indication in the European Union, based on positive Phase 3 LAVENDER study results.
ACADIA Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:ACAD)
This article provides an overview of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates such as earnings, revenue, market capitalization, and EBITDA, while also offering answers to frequently asked questions about the stock.
ACAD Forecast — Price Target — Prediction for 2027
This article provides a forecast for ACADIA Pharmaceuticals Inc. (ACAD) stock, including a consensus price target of 31.65 USD based on 20 analysts. It details the company's current stock performance, market capitalization, and upcoming earnings report. The piece also includes frequently asked questions about ACAD, such as historical prices, volatility, and financial data, and offers technical analysis recommendations.
The Technical Signals Behind (ACAD) That Institutions Follow
This article provides a technical analysis of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), highlighting a strong near-term sentiment with a neutral mid and long-term outlook. It identifies an exceptional 44.7:1 risk-reward setup targeting a 12.0% gain against a 0.3% risk. The analysis also details three institutional trading strategies tailored for different risk profiles, including position trading, momentum breakout, and risk hedging strategies.
ACADIA Pharmaceuticals (ACAD) Stock Could Be 23.2% Undervalued After Guidance Reaffirmed
ACADIA Pharmaceuticals (ACAD) stock is considered 23.2% undervalued, with a fair value of $28.75 compared to its current price of $22.09. Despite recent positive short-term share price momentum, the stock has seen a year-to-date decline, and its valuation hinges on sustained revenue growth and improving profit margins, balancing clinical ambition with financial discipline. Investors should review the underlying data and potential risks, including reliance on core products, before making investment decisions.
ACADIA Pharmaceuticals (ACAD) Stock Could Be 23.2% Undervalued After Guidance Reaffirmed
ACADIA Pharmaceuticals (ACAD) stock is considered 23.2% undervalued, trading at $22.09 against a fair value of $28.75. The company recently filed a shelf registration related to its employee stock ownership plan, and despite a year-to-date share price decline, short-term momentum shows improvement. The valuation narrative highlights sustained revenue growth and improving profit margins, though risks remain due to reliance on core products and potential regulatory setbacks.
ACADIA Pharmaceuticals Inc (ACAD) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for ACADIA Pharmaceuticals Inc (ACAD), detailing its volatility, financial risk, and investment risk. ACAD has a beta of 0.84, suggesting it tends to underperform in up markets but decline less in down markets. The company's risk assessment score is 7.68, placing it 8th out of 389 in the Biotechnology & Medical Research industry.
ACADIA Pharmaceuticals Inc (ACAD) Institutional Confidence
ACADIA Pharmaceuticals Inc (ACAD) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional investors hold 95.66% of shares, a 13.87% decrease quarter-over-quarter. Steven Cohen is the largest institutional shareholder with 2.71 million shares, representing 1.51% of outstanding shares.
How Investors May Respond To ACADIA Pharmaceuticals (ACAD) ESOP-Linked Shelf Registration And Potential Dilution
ACADIA Pharmaceuticals recently filed a shelf registration for up to US$113.78 million, covering 5,209,670 shares for an employee stock ownership plan (ESOP). While this move aims to expand employee incentives, it raises concerns about potential share dilution that could impact the company's investment narrative. The modest scale of this particular registration doesn't significantly alter near-term drivers, but investors should still consider how even slight dilution interacts with ACADIA's concentrated reliance on key products like NUPLAZID and DAYBUE.
How Investors May Respond To ACADIA Pharmaceuticals (ACAD) ESOP-Linked Shelf Registration And Potential Dilution
ACADIA Pharmaceuticals recently filed a shelf registration for up to US$113.78 million, tied to an employee stock ownership plan, which could lead to potential share dilution. While this is a relatively modest amount, investors are advised to consider how it interacts with the company's reliance on key products like NUPLAZID and DAYBUE and its 2026 revenue guidance. The article suggests reassessing growth paths in light of this potential dilution and other financial metrics.
How Investors May Respond To ACADIA Pharmaceuticals (ACAD) ESOP-Linked Shelf Registration And Potential Dilution
ACADIA Pharmaceuticals recently filed a shelf registration for up to US$113.78 million, covering shares tied to an employee stock ownership plan (ESOP). This move signals an expansion of equity-based employee incentives, prompting questions about potential dilution and its impact on the company's investment narrative. While the initial dilution is modest, investors should consider how it interacts with ACADIA's reliance on key products like NUPLAZID and DAYBUE and its 2026 revenue guidance.
ACADIA Pharmaceuticals Inc (ACAD) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of ACADIA Pharmaceuticals Inc (ACAD)'s financial health, highlighting its robust status and high operating efficiency. The company's financial score is 9.16, ranking 13th in its industry, with recent quarterly revenue increasing by 9.72% and net profit by 80.84% year-over-year. The report details specific financial dimensions such as cash and cash equivalents, quality of earnings, operational efficiency, growth potential, and shareholder returns.
ACADIA Pharmaceuticals Inc (ACAD) Earnings Forecast: Future EPS & Revenue Growth Estimates
ACADIA Pharmaceuticals Inc (ACAD) has an earnings forecast score of 7.90, ranking 270 out of 389 in its industry. Analysts have an average price target of $30.00 for ACADIA, with a consensus "Buy" rating based on 21 analysts. The company's expected revenue for the next quarter is $296.64M, and its EPS for the previous quarter was $1.61, with an expected $0.06 for the next quarter.
ACADIA Pharmaceuticals Inc (ACAD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of ACADIA Pharmaceuticals Inc (ACAD) shareholder structure, listing major shareholders and their proportions, as well as the types of investor entities holding stakes. It also includes institutional shareholding history and recent shareholder activity with changes in holdings for key investors. Additionally, the article lists related ETFs that include ACADIA Pharmaceuticals in their portfolios.
ACADIA Pharmaceuticals Inc
This article provides a revenue breakdown for ACADIA Pharmaceuticals Inc (ACAD), detailing its performance by business segments. As of the latest update, the company's revenue primarily comes from NUPLAZID and DAYBUE. NUPLAZID accounts for 63.47% of the revenue with $680.09M, while DAYBUE contributes 36.53% with $391.42M.
Precision Trading with Acadia Pharmaceuticals Inc. (ACAD) Risk Zones
This article from Stock Traders Daily provides a detailed AI-driven analysis of Acadia Pharmaceuticals Inc. (ACAD), highlighting a potential 14.0% gain with minimal risk due to weak near-term sentiment and a mid-channel oscillation pattern. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, based on multi-timeframe signal analysis. The report emphasizes the exceptional risk-reward setup and offers real-time signals and customized risk models for subscribers.
Precision Trading with Acadia Pharmaceuticals Inc. (ACAD) Risk Zones
This article analyzes Acadia Pharmaceuticals Inc. (ACAD), highlighting a weak near-term sentiment and a mid-channel oscillation pattern. It presents three AI-generated trading strategies with specific entry, target, and stop-loss zones for different risk profiles, emphasizing risk-reward setups and multi-timeframe signal analysis.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of "Moderate Buy" by Analysts
ACADIA Pharmaceuticals (NASDAQ:ACAD) has received a "Moderate Buy" rating from analysts, with an average 12-month price target of $31.63. Despite missing recent quarterly earnings and revenue estimates, the company's revenue still grew 9.7% year-over-year. Insiders have recently sold shares, and institutional investors have adjusted their holdings in the biopharmaceutical company.
ACADIA Pharmaceuticals stock (US0042251084): earnings momentum and pipeline focus in neuroscience
ACADIA Pharmaceuticals focuses on neuroscience, with its business model centered on developing and commercializing small-molecule drugs for central nervous system disorders. The company's revenue is primarily driven by its marketed neurology therapy in the US, supported by ongoing R&D investments to expand its pipeline into new indications. The stock is attractive to investors comfortable with clinical and regulatory risks in the biotech sector, given its specialization in a therapeutic area with significant unmet medical need.
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Show Mixed Recent Momentum
ACADIA Pharmaceuticals (ACAD) has shown mixed stock performance recently, with short-term gains but longer-term declines, valuing the company at US$3.7 billion. Despite generating US$1,095.25 million in revenue and US$375.65 million in net income, current valuations suggest the stock may be undervalued, with a fair value estimated at $28.75 compared to its last close of $21.84. This potential undervaluation is attributed to market caution regarding pipeline expansion and growth durability, but any positive developments could quickly shift sentiment.
ACADIA Pharmaceuticals stock (US0042251084): focus on Neurology and rare disease pipeline after latest updates
ACADIA Pharmaceuticals (NASDAQ: ACAD) is a US biopharmaceutical company specializing in neurological and rare diseases, with a focus on areas with high unmet medical needs. The company's strategy includes both commercialized therapies and a late-stage pipeline, targeting conditions like Parkinson's disease-related psychosis and Rett syndrome. Its strong presence in the US market means its performance is closely tied to domestic regulatory decisions, clinical trial outcomes, and payer dynamics.
ACADIA Pharmaceuticals spotlights Alzheimer's psychosis pipeline, NUPLAZID and DAYBUE growth
The article from MSN has no content and therefore cannot be summarized. It appears to be an empty or placeholder article about ACADIA Pharmaceuticals and its pipeline for Alzheimer's psychosis, including NUPLAZID and DAYBUE. No further details are available.
Baker funds tied to ACAD (ACAD) report RSU and stock option grants
Baker Bros. Advisors LP reported acquisition or exercise transactions for ACADIA PHARMACEUTICALS INC, including 18,622 restricted stock units and 32,008 non-qualified stock options. These grants are linked to board service by Julian C. Baker and Dr. Stephen R. Biggar, with the Baker funds holding an indirect pecuniary interest. The stock options have a strike price of $21.66 and vest in quarterly installments starting May 29, 2026.
Technical Reactions to ACAD Trends in Macro Strategies
The article analyzes Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) using AI models, highlighting divergent sentiment across trading horizons indicating choppiness. It presents institutional trading strategies for different risk profiles, including a long position, a momentum breakout, and a risk-hedging short position, alongside multi-timeframe signal analysis with specific support and resistance levels. The report emphasizes a significant risk-reward setup targeting a 14.0% gain versus 0.3% risk.
ACADIA (NASDAQ: ACAD) director granted RSUs and stock options
ACADIA Pharmaceuticals director James M. Daly reported equity compensation activities on May 29, 2026. He exercised 8,107 previously granted restricted stock units and was subsequently granted 9,311 new restricted stock units and 16,004 director stock options with an exercise price of $21.66. After these transactions, Daly directly holds 12,148 common shares.
ACAD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an analysis of ACADIA Pharmaceuticals Inc.'s (ACAD) financials, focusing on its revenue breakdown, profitability margins, and competitive positioning. NUPLAZID is identified as the largest revenue contributor, and the company's gross margin is highlighted at 90.75%, contrasting with its operating and net margins. The piece also benchmarks ACAD against industry competitors like KNSA and CRNX.
ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant
ACADIA Pharmaceuticals director Edmund Harrigan exercised 8,107 restricted stock units into common stock and subsequently received new grants of 9,311 restricted stock units and 16,004 director stock options on May 29, 2026. These transactions, which are compensation-related equity activities and not open-market trades, increase his direct common stock holdings to 43,148 shares. The new RSUs and options include vesting schedules over approximately one year, designed to align his compensation with shareholder outcomes.
ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards
ACADIA PHARMACEUTICALS director Elizabeth A. Garofalo reported equity compensation activities, including exercising 8,107 restricted stock units (RSUs) into common stock and receiving new grants of 9,311 RSUs and 16,004 director stock options. Post-transaction, her direct common stock holdings increased to 33,489 shares. The new RSUs and stock options have specific vesting schedules, and Garofalo has elected to defer the receipt of shares from the new RSUs until future triggers.
ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares
ACADIA Pharmaceuticals Inc. director Jonathan Poole reported equity compensation activity in a recent Form 4 filing. He exercised derivative securities for 2,010 shares of common stock, and also received grants of 9,311 restricted stock units (RSUs) and 16,004 director stock options. These transactions represent routine director compensation rather than open-market trading.
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan
Acadia Pharmaceuticals (ACAD) shareholders approved the election of three Class I directors, the compensation plan for executive officers, and the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2026. They also authorized an increase of 5,209,670 shares for the company's equity incentive plan, which aims to attract and retain talent by using stock-based compensation, potentially leading to future dilution. The company's stock currently holds a Hold rating with a $23.00 price target from analysts, while TipRanks' AI Analyst, Spark, rates it as Neutral due to improved profitability and a strong balance sheet but notes high valuation.
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan
Acadia Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders where shareholders elected three Class I directors, approved executive compensation, ratified Ernst & Young LLP as auditor, and increased shares for its equity incentive plan. These decisions reinforce leadership, governance, and financial oversight, while the expanded equity plan aims to attract and retain talent through stock-based compensation. Analyst ratings on ACAD stock suggest a "Hold" with a $23.00 price target.
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $38
This article provides a quick overview of analyst ratings for ACADIA Pharmaceuticals (ACAD.US), noting a forecast price target range of $24 to $38. It compiles recent assessments from various financial institutions regarding the company's stock performance. The report aims to give investors a concise summary of current expert opinions on ACADIA Pharmaceuticals.
Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan
Acadia Pharmaceuticals stockholders have approved an amendment to the company's 2024 Equity Incentive Plan, increasing the number of authorized common shares for issuance by 5,209,670. This decision, made at the 2026 Annual Meeting, followed prior board approval and aims to support future equity-based compensation. Additionally, three Class I directors were elected, and other proposals received strong stockholder support.
